

Dissecting resistance mechanisms in melanoma combination therapy

Eunjung Kim – PSOC member and Alexander Anderson, ICBP member, PSOC member

Abstract— We present a compartment model that explains melanoma cell response and resistance to mono and combination therapies. Model parameters were estimated by utilizing an optimization algorithm to identify parameters that minimized the difference between predicted cell populations and experimentally measured cell numbers. The model was then validated with *in vitro* experimental data. Our simulations show that although a specific timing of the combination therapy is effective in controlling tumor cell populations over an extended period of time, the treatment eventually fails. We subsequently predict a more optimal combination therapy that incorporates an additional drug at the right moment.

I. MELANOMA RESPONSE AND RESISTANCE TO THERAPY

Metastatic melanoma is known to be resistant to chemotherapy (chemo). During the last few years, targeted therapeutic approaches have emerged as the dominant treatment choice, mainly because they target tumor cells that harbor specific genetic mutations. However, even these targeted drugs have limited long term success in treating melanoma metastatic patients, since resistance eventually emerges. Unexpectedly, when chemotherapy and a targeted treatment (AKT inhibitor, AKTi) are given in combination to metastatic melanoma patients, long-term responses were recently observed [1]. Although little is known regarding why such combinations are more successful, we suggested one possible mechanism, specifically differential induction of autophagy by mono or combination therapy [1]. To better understand how autophagy might facilitate treatment response, we developed a mathematical model comprising of a system of ordinary differential equations that explains the dynamics of melanoma cells under mono (either chemo or




Figure 1. Compartmental model schematic showing how non-autophagy, quiescent and physiological autophagy interact in response to therapies.

Research supported by PSOC U54CA143970.

E. Kim and A. R. A. Anderson are with the Integrated Mathematical Oncology Department, Moffitt Cancer Center, TAMPA, FL 33647, USA (e-mail: Eunjung.Kim@moffitt.org and Alexander.Anderson@moffitt.org).




Figure 2. A. Calibrating the model with *in vitro* data. B. Validating model predictions with *in vitro* combination therapy.

AKTi alone) and combination therapy of the two [2]. The model is composed of three compartments, non-autophagy and two autophagy compartments (physiological and quiescent autophagy) based on experimental observations showing that some autophagy cells continue to maintain normal cell homeostasis [3-6]. Fig.1 shows how these three compartments interact with one another, switching rates are altered depending on the treatment being administered.

II. MODEL CALIBRATION AND VALIDATION

Model parameters were estimated by using the implicit filtering method to generate fitted curves describing the growth of a melanoma cell line under no treatment, mono and combination therapy (Fig. 2A). We then used the fitted model to predict the effects of 12 different schedules including no treatment, single agent therapy, concurrent combination therapy, and single agent sequential therapy of two drugs. We accurately predicted total population at day 16 in equivalent *in vitro* experiments (Fig. 2B). Interestingly, our longer-term simulation over 40 days showed that the combination therapy was effective in controlling tumor population over an extended period of time. The resistance, however, emerges (Fig. 3A) driven by the autophagy population, even for the proposed best strategy (#7 in Fig. 2B, concurrent treatment of chemo and AKTi followed by AKTi maintenance). To overcome this resistance, we




Figure 3. A, 40-day simulation of best combination schedule (#7 in Fig. 2B). B, Addition of CQ on day 30 significantly improves response.

applied a drug that targets the autophagy population (chloroquine (CQ)) and were able to show that additional administrations of this drug inhibited resistance (Fig. 3B).

III. QUICK GUIDE TO THE METHODS (1 PAGE)

A. Model development

Compartment models are often used to describe transport of material in biological systems. Our compartment model contains three compartments, each containing a well mixed cell population with different autophagy phenotypes. In Fig. 1, boxes represent compartments and arrows represent the connections between the compartments. Every compartment has a number of connections leading to the box and a number of arrows leading from the box. Cells can either flow from one compartment to another, be added to themselves (growth) or they can be removed by death.

In our model (Fig. 1), non-autophagy melanoma cells proliferate (rate: g_N), and following treatment can acquire either a physiological autophagy phenotype (rate: a_P) or a quiescent autophagy phenotype (rate: b_Q). Physiological autophagy cells grow (rate: g_P) and can revert to non-autophagy cells (rate: r_P), or enter a quiescent/senescent state (rate: q_P). Tumor cells having the quiescent autophagy phenotype do not divide, yet these cells can reacquire a physiological autophagy phenotype (rate: r_Q) or a non-autophagy phenotype (rate: r_N) state. Cells in each compartment die at a fixed rate ($d_{N,P,Q}$). To model the increased cell death observed in our experimental data, on days 6-9, we included a delay in the model – specifically for the cell death of quiescent autophagy cells (rate: τ).

The effects of chemo, AKTi and their combination were also incorporated into the model. As our cell culture experiments showed that chemo triggered cell death with negligible effects on autophagy [1], it was assumed that chemo only augmented cell death. Further, as chemo is effective only in proliferating melanoma populations, we assumed that the therapy increases the death rate of the two proliferating phenotypes, non-autophagy (d_N) and physiological autophagy cells (d_P). We also assumed that the frequency with which cells became quiescent (q_P) increased with chemo. *In vitro* studies showed that while AKTi did not augment cell deaths or effectively inhibit melanoma cell growth, it induced autophagy [1]. Therefore, we assumed that AKTi increases the rate of transitioning to the autophagy phenotypes, a_P and b_Q . As combination therapy does not augment cell death compared with chemo,

nor significantly increase autophagy relative to AKTi, the combination of the two treatments was modeled by adding the effects of chemo and AKTi. Finally, it was assumed that cell which switch compartment under treatment can only revert back to their original states after treatment is removed. The schematic representation of this compartment converts readily into a system of ordinary differential equations:

$$\begin{aligned}\dot{N} &= (g_N - d_N)N - (a_P + b_Q)N + (1-A)r_P P + (1-A)(1-C)r_N Q, \\ \dot{P} &= (g_P - d_P)P + a_P N - (1-A)r_P P - q_P P + (1-A)(1-C)r_Q Q, \\ \dot{Q} &= -\left(d_Q + \frac{d_\tau}{1 + e^{-(t-\tau)}}\right)Q - (1-A)(1-C)(r_N + r_P)Q + b_Q N + q_P P,\end{aligned}\quad (1)$$

where $d_N = d_0 + c_N$, $d_P = d_0 + c_P C$, $q_P = q_0 + c_Q C$, $a_P = a_0 + a_N A$, and $b_Q = b_0 + b_P A$. In equation (1), A and C are defined by

$$A, C = \begin{cases} 0 & \text{drug is off,} \\ 1 & \text{drug is on.} \end{cases}$$

B. Parameter estimation

Both initial cell populations and the growth rate of non-autophagy cells (g_N) are estimated by assuming an exponential growth of untreated cells and finding both the initial value and exponent of the best-fit curve. We used an optimization algorithm called implicit filtering [7] to determine the best remaining parameter set H (except g_N) that minimized the difference between the predicted number of cells (N_P) and experimental results (N_E) in 4 conditions: no treatment (n); chemo (c); AKTi (a); and combination (m). The mathematical definition of our problem is:

$$\min_{H \in \Omega} f(H) = \min_{H \in \Omega} \sqrt{\sum_{i \in \{n, c, a, m\}} (N_{P_i}(H) - N_{E_i})^2},$$

where the goal is to minimize the objective function f subject to the condition that $H \in \mathbb{R}^N$ is in the feasible region:

$$\Omega = \{H \in \mathbb{R}^N | L_j \leq H_j \leq U_j\},$$

where L_j and U_j are the upper and lower bound on the j th component H_j of the vector H .

C. Other applications

The Compartment modeling approach assumes that material in the compartment is well mixed and homogeneous. The approach can't capture spatial dynamics, individual diversity (heterogeneity), or stochastic effects. However, the approach is computational efficient, can describe complex systems (interactions) in a simple way, and is easy to formulate. It is especially useful to model interactions between different states of homogeneous compartments. In cancer modeling field, many compartment models have been developed to model tumor progression [8-17], tumor-stromal interactions [18], tumor-immune interactions [16, 17, 19-32], drug resistance [2, 33], and drug distribution in the body [34]. This approach can also model other biological systems (e.g. ecological) where the material is energy (food) and the compartments represent different species of animals and plants [35]. It has also been widely used to model spread of infectious disease, where compartments represent health status with respect to the pathogen in the system (e.g., susceptible, infectious or recovered) [36, 37].

REFERENCES

- [1] V. W. Rebecca, R. R. Massaro, I. V. Fedorenko, V. K. Sondak, A. R. Anderson, E. Kim, *et al.*, "Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma," *Pigment Cell Melanoma Res*, vol. 27, pp. 465-78, May 2014.
- [2] E. Kim, V. W. Rebecca, K. S. Smalley, and A. R. Anderson, "Phase I trials in melanoma: A framework to translate preclinical findings to the clinic (submitted)."
- [3] M. L. Bristol, X. Di, M. J. Beckman, E. N. Wilson, S. C. Henderson, A. Maiti, *et al.*, "Dual functions of autophagy in the response of breast tumor cells to radiation: cytoprotective autophagy with radiation alone and cytotoxic autophagy in radiosensitization by vitamin D 3," *Autophagy*, vol. 8, pp. 739-53, May 1 2012.
- [4] D. A. Gewirtz, "The four faces of autophagy: implications for cancer therapy," *Cancer Res*, vol. 74, pp. 647-51, Feb 1 2014.
- [5] Y. Liu and B. Levine, "Autosis and autophagic cell death: the dark side of autophagy," *Cell Death Differ*, vol. 22, pp. 367-376, Mar 2015.
- [6] S. Pattingre, A. Tassa, X. Qu, R. Garuti, X. H. Liang, N. Mizushima, *et al.*, "Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy," *Cell*, vol. 122, pp. 927-39, Sep 23 2005.
- [7] C. T. Kelley, *Implicit filtering*. Philadelphia: Society for Industrial and Applied Mathematics, 2011.
- [8] I. Shuryak, R. K. Sachs, L. Hlatky, M. P. Little, P. Hahnfeldt, and D. J. Brenner, "Radiation-induced leukemia at doses relevant to radiation therapy: Modeling mechanisms and estimating risks," *Journal of the National Cancer Institute*, vol. 98, pp. 1794-1806, Dec 20 2006.
- [9] R. K. Sachs, K. Johnsson, P. Hahnfeldt, J. Luo, A. Chen, and L. Hlatky, "A Multicellular Basis for the Origination of Blast Crisis in Chronic Myeloid Leukemia," *Cancer Research*, vol. 71, pp. 2838-2847, Apr 15 2011.
- [10] M. D. Johnston, C. M. Edwards, W. F. Bodmer, P. K. Maini, and S. J. Chapman, "Mathematical modeling of cell population dynamics in the colonic crypt and in colorectal cancer," *Proc Natl Acad Sci U S A*, vol. 104, pp. 4008-13, Mar 6 2007.
- [11] H. V. Jain, S. K. Clinton, A. Bhinder, and A. Friedman, "Mathematical modeling of prostate cancer progression in response to androgen ablation therapy," *Proc Natl Acad Sci U S A*, vol. 108, pp. 19701-6, Dec 6 2011.
- [12] N. Hartung, S. Mollard, D. Barbolosi, A. Benabdallah, G. Chapuisat, G. Henry, *et al.*, "Mathematical modeling of tumor growth and metastatic spreading: validation in tumor-bearing mice," *Cancer Res*, vol. 74, pp. 6397-407, Nov 15 2014.
- [13] R. A. Gatenby and T. L. Vincent, "Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies," *Molecular Cancer Therapeutics*, vol. 2, pp. 919-927, Sep 2003.
- [14] R. A. Gatenby, "Population ecology issues in tumor growth," *Cancer Res*, vol. 51, pp. 2542-7, May 15 1991.
- [15] H. Enderling and M. A. Chaplain, "Mathematical modeling of tumor growth and treatment," *Curr Pharm Des*, vol. 20, pp. 4934-40, 2014.
- [16] L. G. De Pillis, K. R. Fister, W. Gu, T. Head, K. Maples, T. Neal, *et al.*, "Optimal control of mixed immunotherapy and chemotherapy of tumors," *Journal of Biological Systems*, vol. 16, pp. 51-80, Mar 2008.
- [17] L. de Pillis, K. R. Fister, W. Q. Gu, C. Collins, M. Daub, D. Gross, *et al.*, "Mathematical model creation for cancer chemo-immunotherapy," *Computational and Mathematical Methods in Medicine*, vol. 10, pp. 165-184, 2009.
- [18] E. H. Flach, V. W. Rebecca, M. Herlyn, K. S. Smalley, and A. R. Anderson, "Fibroblasts contribute to melanoma tumor growth and drug resistance," *Mol Pharm*, vol. 8, pp. 2039-49, Dec 5 2011.
- [19] J. C. Arciero, T. L. Jackson, and D. E. Kirschner, "A mathematical model of tumor-immune evasion and siRNA treatment," *Discrete and Continuous Dynamical Systems-Series B*, vol. 4, pp. 39-58, Feb 2004.
- [20] N. J. Burroughs, B. Miguel Paz Mendes de Oliveira, and A. Adrego Pinto, "Regulatory T cell adjustment of quorum growth thresholds and the control of local immune responses," *J Theor Biol*, vol. 241, pp. 134-41, Jul 7 2006.
- [21] A. d'Onofrio, "A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferences," *Physica D-Nonlinear Phenomena*, vol. 208, pp. 220-235, Sep 1 2005.
- [22] L. G. de Pillis, A. E. Radunskaya, and C. L. Wiseman, "A validated mathematical model of cell-mediated immune response to tumor growth," *Cancer Res*, vol. 65, pp. 7950-8, Sep 1 2005.
- [23] H. P. de Vladar and J. A. Gonzalez, "Dynamic response of cancer under the influence of immunological activity and therapy," *Journal of Theoretical Biology*, vol. 240, pp. 162-163, May 7 2006.
- [24] D. Fouchet and R. Regoes, "A population dynamics analysis of the interaction between adaptive regulatory T cells and antigen presenting cells," *PLoS One*, vol. 3, p. e2306, 2008.
- [25] P. S. Kim, P. P. Lee, and D. Levy, "Modeling regulation mechanisms in the immune system," *J Theor Biol*, vol. 246, pp. 33-69, May 7 2007.
- [26] P. S. Kim, P. P. Lee, and D. Levy, "Dynamics and potential impact of the immune response to chronic myelogenous leukemia," *PLoS Comput Biol*, vol. 4, p. e1000095, Jun 2008.
- [27] K. Leon, A. Lage, and J. Carneiro, "Tolerance and immunity in a mathematical model of T-cell mediated suppression," *J Theor Biol*, vol. 225, pp. 107-26, Nov 7 2003.
- [28] S. J. Merrill, "A model of the role of natural killer cells in immune surveillance-II," *J Math Biol*, vol. 17, pp. 153-62, 1983.
- [29] H. Moore and N. K. Li, "A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction," *J Theor Biol*, vol. 227, pp. 513-23, Apr 21 2004.
- [30] M. Robertson-Tessi, A. El-Kareh, and A. Goriely, "A mathematical model of tumor-immune interactions," *J Theor Biol*, vol. 294, pp. 56-73, Feb 7 2012.
- [31] G. Shahaf, K. Johnson, and R. Mehr, "B cell development in aging mice: lessons from mathematical modeling," *Int Immunol*, vol. 18, pp. 31-9, Jan 2006.
- [32] F. J. Varela and J. Stewart, "Dynamics of a class of immune networks. I. Global stability of idiosyncratic interactions," *J Theor Biol*, vol. 144, pp. 93-101, May 10 1990.
- [33] C. Tomasetti and D. Levy, "An elementary approach to modeling drug resistance in cancer," *Math Biosci Eng*, vol. 7, pp. 905-18, Oct 2010.
- [34] K. J. Himmelstein and R. J. Lutz, "A review of the applications of physiologically based pharmacokinetic modeling," *J Pharmacokinet Biopharm*, vol. 7, pp. 127-45, Apr 1979.
- [35] H. T. Odum, "Explanations of ecological relationships with energy systems concepts," *Ecological Modelling*, vol. 158, pp. 201-211, Dec 31 2002.
- [36] R. M. Anderson and R. M. May, *Infectious diseases of humans : dynamics and control*. Oxford: Oxford University Press, 1991.
- [37] N. T. J. Bailey, *The mathematical theory of infectious diseases and its applications*, 2nd ed. London: Griffin, 1975.